United States Considers Peptide Reclassification
A regulatory update announced in February 2026 could impact the advancement of peptide-based therapies in the United States. HHS Secretary Robert F. Kennedy Jr. stated that the U.S. Food and Drug Administration is considering moving 14 peptides currently classified under Category 2 to Category 1 within its regulatory system. If confirmed, the change would allow […]